. Actions of ANG II on the proximal tubule AT 1 R contribute to the regulation of salt and fluid homeostasis and blood pressure (BP) (20) . Increased activation of AT 1 R in the proximal tubule can lead to excessive salt retention, oxidative stress, inflammation, hypertension, and ultimately chronic kidney disease (20, 25) . Hence, blockade with AT 1 R blockers (ARBs) is an important treatment for hypertension and associated cardiovascular and kidney disease (9) . However, antihypertensive responses to ARBs vary in different patient populations, suggesting that polymorphisms of the PTC AT 1 R may play a role in differential BP responses to ARBs (1, 27, 34, 37) .
There is mounting interest in the polymorphisms in the reninangiotensin system (RAS) that contribute to race, sex, and other demographic variations in BP responses to ARBs (12, 13, 16, 19, 22, 27, 34, 35, 37, 39) . For example, AT 1 R polymorphisms, including A1166C (3=-untranslated region), have been studied with respect to their propensity to confer increased risk for hypertension and cardiovascular and chronic kidney disease (35) . However, polymorphisms in the AT 1 R that alter the coding sequence that may alter ARB binding to PTCs and thus variably affect salt retention and BP have not been well established. Nevertheless, one polymorphism (T282M 7.35) has been reported on the National Center for Biotechnology and Information (NCBI) website to be associated with renal tubular agenesis (27) . Recently, another polymorphism in the human AT 1 R (A163T 5.60) has been proposed to result in decreased binding of losartan to the AT 1 R and was identified in a polymorphism screen to confer increased risk for chronic kidney disease in a Japanese cohort (1, 39) . Although differences in the genetic makeup of individuals are well-recognized, systematic studies on human AT 1 R polymorphisms and ARB resistance have not been undertaken (27) .
ARBs bind to the AT 1 R via a pocket that partially overlaps with that for ANG II, as expected for a competitive antagonist. Based on current evidence, the ANG II-binding pocket is formed by: K102 (3.26 in the Ballesteros-Weinstein numbering system), H166 and R167 in the second extracellular loop (ECL2), and E173 in the ␣-helix within ECL2, K199 (5.42), W253 (6.47), F259 (6.54), T260 (6.55), D263 (6.58), and D281 (7.34) (Fig. 1) (3, 21, 26, 38 ). ARBs (biphenyl compounds with tetrazole and imidazole rings) bind to AT 1 Rs via residues shared with ANG II (K102, H166, R167, K199, and D263) as well as unique residues [V108 (3.32), N111 (3.35), A163 (4.60), and S252 (6.46)] with minor or unclear contributions from other sites ( Fig. 1) (4, 21, 26, 38) . Importantly, a single mutation, V108I (3.32) , leads to a 40-fold reduction in binding for losartan, a prototype of the ARBs, but does not alter ANG II binding (17) . Thus, single polymorphisms can substantially influence ARB binding and clinical responses.
During our investigation, we came across the genomic sequence of opossum AT 1 R that has several variations in the ARB-binding pocket compared with the human AT 1 R. AT 1 Rs are known to be expressed in abundance by PTCs on both the luminal brush border and the basolateral (BL) region (5, 8, 23, 28) , suggesting their importance in renal sodium retention and BP regulation. Therefore, we posited that exploring the effect of ARBs on ANG II-binding characteristics and ANG II-mediated signaling in opossum PTCs would increase our understanding of the role of polymorphisms in modulating the efficacy of various ARBs in lowering BP in various populations.
Findings in the native OKP cell line are compared with an existing and well-characterized stable rat AT 1A R-expressing OKP cell line (36) . The rat AT 1A R is remarkably well conserved compared with the human AT 1 R, especially with regard to ANG II-and ARB-binding pockets, deeming it a good substitute for human receptor studies when examining binding of ANG II and ARBs. Evidence is presented for lack of effective ARB blockade of ANG II binding to, and signaling through, the opossum AT 1 R despite functional expression of AT 1 Rs in the native opossum proximal tubule (OKP) cells. These observations are consistent with experimentally demonstrated variations/polymorphisms that inhibit ARB binding in humans and other species. These findings advance our understanding of opossum AT 1 R and support the continued use of OKP cells for studying ANG II-AT 1 R signaling. Moreover, these data highlight the potential to ascertain amino acid variations in the ARB-binding pocket of the human AT 1 R as a genetic test to evaluate the therapeutic efficacy of ARBs.
MATERIALS AND METHODS

PTC Culture
Native OKP cells were a kind gift from Dr. D. Biemesderfer at Yale University. T35OK-AT1R stably expressing rat AT1AR in OKP cells (ATCC, Dr. John Raymond, Medical University of South Carolina) were generated in the laboratory of Dr. T. Thekkumkara at Texas Tech University (Amarillo, TX). Native OKP cells were grown in DMEM-F-12 with 10% FBS and 100 g/ml penicillin/streptomycin. T35OK-AT 1R cell medium also contained 200 g/ml G418, transferrin, insulin, dexamethasone, and epidermal growth factor. Both cell lines were starved in media containing 0.1% FBS, with the T35OK-AT1R starvation medium additionally containing G418.
PCR and Sequencing
Opossum-specific PCR primers were designed based on the AT1R sequence (XM_001371246.1) published at the NCBI website: forward primer (F1) 5=-ATG GCC AAA GTG ACC TGC ATT-3= and reverse primer (R1) 5=-TGA ATC TCA TAA GCC TTT TTC-3= are based entirely in exon 4 for the 248-bp product. In addition, to confirm that the sequence of AT 1R in the native OKP cell line is similar to NCBI published sequences, primer sets were designed to flank the entire open reading frame (ORF) for a total of ϳ1.2 kb with the following primers: forward primer (F2) 5=-CCCCCAAGATCATGCTGGCA-TAGC-3= and reverse primer (R2) 5=-TCCAAGGATGGAAACCCT-TGCCAT-3=. Genomic DNA was extracted with the "Blood and cell culture" DNA midi kit (Qiagen, Valencia, CA) on previously frozen OKP cells, as per the manufacturer's protocol. PTC genomic DNA was used as a template to PCR amplify the putative AT 1R gene ORF by employing the "Long-Amp Taq" PCR kit (New England Bio-labs, Ipswich, MA). The thermocycling steps in the generation of OKP AT 1R gene product were optimized as per the manufacturer's recommendations, except for addition of Taq polymerase after the "hotstart" step. The following thermocycling conditions were used: initial (21) by blue lines with an orange-shaded S. Red residues denote involvement in ANG II binding, blue residues denote involvement in angiotensin receptor blocker (ARB) binding, orange residues indicate that the residue has minor contributions to ANG II binding, and yellow residues indicate that the residue has minor or questionable contributions to ARB binding. Overlapping yellow and orange shaded circles indicate both ARB and ANG II binding to a residue. White lettering depicts notable differences between the human and opossum sequences, and the numbers indicate the most conserved residue according to the BallesterosWeinstein system (5).
denaturing at 94°C for 4 min, followed by 30 cycles at 94°C for 30 s, 55°C for 1 min, and 65°C for 2 min each for denaturing, annealing, and synthesis, respectively (the time for the latter cycle of synthesis at 65°C for 2 min was increased by 15 s every one cycle after the first cycle), followed by a final elongation step at 65°C for 10 min. The ϳ1.2-kb product was eluted from agarose gel and purified using the "Qia-quick" gel-extraction kit (Qiagen). Sequencing was done at the DNA Core facility at the University of Missouri-Columbia using a standard protocol. The genomic sequence was converted to protein sequence using the ORF finder (http://www.ncbi.nlm.nih.gov/ projects/gorf/orfig.cgi). The ORF obtained thus was aligned to XP_001371283.1 using ClustalW.
AT 1R Protein Sequences
The NCBI database was used to search for published AT1R protein sequences [Supplemental Table 1 (Supplemental data for this article may be found on the American Journal of Physiology: Renal Physiology website.)]. The sequences were compared via the ClustalW sequence alignment tool, and phylogenetic comparison was computed in Bioedit (14) and viewed in Treeview (29) . The ANG II and ARB-binding pockets were graphically analyzed utilizing WebLogo (11) .
Jak2 Phosphorylation by Western Blot
Western blots were done using standard techniques. Briefly, monolayers were starved overnight and treated with the indicated ARBs for 1 h before ANG II stimulation for 15 min. Whole cell lysates were prepared in lysis buffer containing 1% Triton X-100, 100 mM NaCl, 20 mM Tris, pH 7.5, 2 mM EDTA, 10 mM MgCl 2, 10 mM NaF, 40 mM ␤-glycerol phosphate, 1 mM phenylmethylsulfonyl fluoride, 2 mM Na3VO4, 10 mg/ml aprotinin, and 10 mg/ml leupeptin with additional protease inhibitors (Roche Applied Science, Indianapolis, IN). Protein quantitation was done with BCA reagent (Pierce, Rockford, IL), and 40 g of protein were loaded in each well. Gels were transferred to nitrocellulose membranes and incubated with antibodies to Jak2 and phospho-Jak2 in 5% BSA with 0.1% TBS-Tween (Cell Signaling, Danvers, MA). Bands were visualized with a Bio-Rad phosphorimager after addition of enhanced chemiluminescence reagent (Pierce) and quantified using Image lab (Bio-Rad, Hercules, CA).
Radioligand Binding
Nonpolarized PTCs. Native OKP cells and T35OK-AT 1R cells were grown to 70 -95% confluence in T-150 flasks, washed with PBS, trypsinized in 0.05% trypsin-EDTA, and centrifuged at 600 g for 5 min, and the cell pellet was resuspended in DMEM containing 50% FBS. Cells (2 ϫ 10 5 to 5 ϫ 10 5 ) were used for radioligand binding. The binding assay was conducted as previously described (30) , except that, for the duration of the binding experiment, the cells were maintained on ice and centrifuged at 4°C. For the competition experiments, nonradioactive ANG II (10 Ϫ11 M through 10 Ϫ5 M) and PD-123319 (10 Ϫ11 M through 10 Ϫ5 M) were added in increasing concentrations; olmesartan (10 Ϫ6 M) was used to verify binding to the AT1R. Data were plotted and analyzed using Graphpad Prism software.
Polarized PTCs. Native OKP cells were grown to 100% confluency on six-well Transwell inserts (Corning, Tewksbury, MA) with 0.4 M pore diameter for 1 wk to form polarized layers. Polarization was confirmed using megalin as the apical (AP) membrane marker. PTCs were starved overnight in DMEM/0.1% FBS, and, on the morning of the experiments, cells were washed in PBS, and DMEM with no phenol red was used for the assays. Blockade of AT 1R was done with olmesartan for 1 h followed by I 125 -labeled ANG II (50 pM; PerkinElmer, Waltham, MA) treatment for 30 min at room temperature to facilitate uptake into cells. I 125 -ANG II binding to AP and BL receptors was assessed separately in individual wells. The inserts were washed three times with ice-cold 1ϫ PBS, and surface-bound receptors were removed with two 40-s acid washes in ice-cold 5 mM trichloroacetic acid in 150 mM NaCl, pH 2.5.
For both sets of experiments, the counts per minute were measured on a 1480 Automatic Gamma Counter (Perkin-Elmer).
Modeling of Human AT 1R
Human AT1R modeling was conducted via computerized prediction (for specifics see below) of the human AT1R and ␤2-adrenergic receptor (␤2-AR) secondary structures from their linear sequences, which resulted in remarkably similar predictions. The predicted ␤2-AR was then compared and refined to match the crystalized ␤2-AR (PBD ID: 3P0G) (32) . The refined ␤2-AR prediction was then used to refine the AT1R prediction, and, when constructing the model in two dimensions (Fig. 1) , the crystalized ␤2-AR was used as a guide. CBS TMHMM and TMpred (15) were used to predict transmembrane (TM) regions, and SCRATCH Protein Predictor was used to run SSpro8 to predict the secondary structures.
Statistics
Results were analyzed using two-way ANOVA, or one-way ANOVA when appropriate, with ␣ set at 0.05 using NCSS 2007 (NCSS, Kaysville, UT) and GraphPad Prism 5 (Graphpad Software, San Diego, CA). Tukey-Kramer and Kruskal-Wallis Z post hoc tests were applied for normal and ratiometric data, respectively, as indicated in Figs. 1-7 and were considered significant only if P Ͻ 0.05. All data are reported as means Ϯ SE.
RESULTS
Native OKP Cells Express the AT 1 R
Utilizing an opossum-specific PCR primer set based on published NCBI sequences, we obtained a 250-bp product in the native OKP cells as well as the T35OK-AT 1 R cells, consistent with the expression of AT 1 R in this cell line (Fig. 2) . We sequenced the 250-bp product and 1.2 kb of genomic DNA containing the entire AT 1 R ORF to confirm that the clonal OKP cells expressed an AT 1 R consistent with published NCBI sequence (Supplemental Fig. 1 ). However, this sequence revealed multiple discrepancies with the human sequence; most notably, there were alterations in the ARB, but not ANG II-binding pockets (Fig. 3) . 
Amino Acid Variations in the OKP AT 1 R Compared with Other Species' AT 1 Rs
We aligned 28 vertebrate AT 1 R protein sequences, utilizing ClustalW to identify areas that are not conserved in the opossum (Supplemental Fig. 2 and Supplemental Table 1 ). All of the ANG II-binding site amino acids in the opossum AT 1 R are conserved when compared with the human AT 1 R (Fig. 1) , and they are relatively conserved across all species examined. They are especially well conserved in mammals, indicating the importance of ANG II in the physiological processes of evolution (Fig. 3A) . In contrast, variations within the ARB-binding pocket are more pronounced (Fig. 3B) . In the opossum, position 108 and 163 amino acids differ from the human, each of which is critical for losartan binding (17) .
Analysis of the genetic distance of the opossum AT 1 R showed that it and the platypus AT 1 R are quite distant from the rest of the mammalian AT 1 Rs (Fig. 4 and Supplemental Table 1 ). Furthermore, the phylogenic tree shows that the AT 1 R sequences follow the pattern of evolution in which fish are the most distant from the humans, followed by amphibians, birds, rodents, and then other mammals.
AT 1 R-Mediated Signaling is Present in OKP Cells but is not Abrogated by Olmesartan
To establish functional expression of the AT 1 R in OKP cells, native OKP cells were treated with ANG II (10 Ϫ7 M) for 15 min, resulting in tyrosine phosphorylation of Jak2 (Fig. 5) .
Jak2 is an established signaling pathway for AT 1 Rs, but not ANG II receptors type 2 (AT 2 Rs). However, olmesartan (10 Ϫ6 M) did not inhibit Jak2 phosphorylation in native OKP cells but ablated ANG II-mediated phosphorylation of Jak2 in the T35OK-AT 1 R cells (Fig. 5A) . Recall the T35OK-AT 1 R cells have a canonical ARB-binding site. To further assess whether the lack of inhibition of ANG II-mediated activation of Jak2 is a class effect of ARBs and not specific to olmesartan, we used four additional ARBs (losartan, valsartan, irbesartan, and azilsartan at doses of 10 Ϫ6 M) and could not inhibit ANG IImediated phosphorylation of Jak2 in native OKP PTCs (Fig.  5B) . ANG II at a very low concentration of 10 Ϫ10 M did not stimulate Jak2 phosphorylation consistently in monolayer or polarized native OKP cells, but 10 Ϫ9 and 10 Ϫ8 M ANG II resulted in mild phosphorylation of Jak2 that was not affected by 10 Ϫ6 M of the five ARBs (data not shown). These data suggests that lack of suppression of ANG II signaling was not the result of growing in a nonpolarized state or insufficient doses of the ARBs.
ANG II Binds to Opossum AT 1 R
Based on the functional and sequence data, we were curious to examine the binding of ANG II and olmesartan to the AT 1 R in the native OKP cell line (Fig. 6) sites on the T35OK-AT 1 R cells as expected (Fig. 6A) . Next, to determine the affinity of the OKP AT 1 R for ANG II, bound 125 I-ANG II was competed with nonradioactive ANG II (Fig.  6B) . The log K d was Ϫ8.0 Ϯ 0.1 and Ϫ7.7 Ϯ 0.1 M for the native OKP and T35OK-AT 1 R cells, respectively. Thus, opossum ANG II receptors bind ANG II with similar affinity as the rat AT 1A R.
AT 1 R-and AT 2 R-Specific Antagonists Cannot Compete for OKP-Specific AT 1 R
Finally, we demonstrate that olmesartan (10 Ϫ6 M) cannot compete with 125 I-ANG II for binding to the AT 1 R in the native OKP cell line but can compete for the rat AT 1A R in the T35OK-AT 1 R cell line (Fig. 6C) . Moreover, in both cell lines, 125 I-ANG II binding was effectively competed by nonradioactive ANG II (10 Ϫ7 M) (Fig. 6C) . We confirmed that 125 I-ANG II did not bind to an AT 2 R via using increasing concentrations of PD-123319 in both cell types (Fig. 6D) . To further assess whether binding to AT 1 R is dependent on PTC polarization, AP and BL receptors were assayed for their ability to internalize 125 I-ANG II (Fig. 7) . AP AT 1 R internalized 125 I-ANG II in slightly lower amounts (not significant) than BL AT 1 R in native OKP PTCs, confirming previous studies (36); however, olmesartan did not block uptake of either AP or BL 125 I-ANG II, confirming that the effects seen are not the result of a lack of polarization of the PTCs.
DISCUSSION
Variable human response to drug treatment is increasingly being attributed to polymorphisms in the genome for many widely used drugs, including ␤-blockers, other G proteincoupled receptor antagonists, statins, and, recently, coumadin (33, 37) . Although the concept of certain amino acid sites in AT 1 R being central to ARB binding dates back ϳ15 years, translation of this concept to human ARB resistance has been delayed primarily because of absence of resources such as the single nucleotide polymorphism (SNP) database, need to sample a larger cohort to get to significant differences (allele Fig. 4 . The phylogenetic tree for the AT1R follows known patters of species evolution. As expected, the opossum is distant from the human and related to the platypus. The cladogram was developed by using a neighborhood prodist tool with no root set. frequency is not known), and difficulty in selecting patient populations (17, 18) . Availability of large-scale sequencing data from the Genome Project and other sister projects has enabled us to effectively use this information to test hypotheses about ARB resistance in novel ways. To put this in perspective, drug resistance attributable to RAS polymorphisms has spurred many investigations in the search to resolve human variations in BP, chronic kidney disease, and cardiovascular disease (12,  13, 16, 19, 22, 27, 35, 39) . In this regard, the A1166C polymorphism in the AT 1 R has been the focus of attention (many dozens of papers), and several humans with this polymorphism have been identified (13, 19) . However, the A1166C polymorphism lies in an area of the 3=-untranslated sequence of the AT 1 R, and its significance is still unclear (12) . More recently, discovery of coding sequence polymorphisms via the SNP database has provided the potential to revolutionize the way we think about drug resistance. For example, the A163T (rs12721226) polymorphism is weakly associated with chronic kidney disease and a 10-mmHg increase in systolic BP (39) . More recent data from the Perindopril Genetic Association Study shows that carriers of greater than or equal to three risk alleles of rs rs275651 (4230TϾA) and rs5182 (Leu191) polymorphisms in AT 1 R were associated with poorer response to angiotensin-converting enzyme inhibitors (37) . The list of SNPs keeps growing and the current list is documented at (http://www.ncbi.nlm.nih.gov/projects/SNP) and summarized in Supplemental Table 2 . Interestingly, at least 33 SNPs have been identified in the coding region of agtr1, the human AT 1 R gene. Of these, many alter the amino acids, and the rest are synonymous (http://www.ncbi.nlm.nih.gov/projects/SNP) (27) .
To test our hypothesis about amino acid variations and ARB resistance, we chose an opossum PTC line that has been well studied with respect to renal sodium transport (4, 36) . Although there are many iterations of this cell line, two of these, the OKP (Cole et al.) and OK (ATCC, John Raymond), have been primarily used by investigators (10, 36) . To be a useful in vitro model for the study of ANG II-mediated effects, AT 1 Rs need to be functionally expressed and pharmacologically blocked. Based on current literature, it is not clear to what extent opossum PTC expresses AT 1 Rs (4, 36). Moreover, pharmacological inhibition with an ARB (losartan) has not conclusively established the presence of an AT 1 R (7, 31).
Currently, identification of receptors is conducted via two methods: genetic and pharmacological. Genetic identification is based solely on sequence homology, which in the case of native OKP cells there is clearly an expressed AT 1 R that is identical to the identified opossum agtr1 (XP_001371283.1) on chromosome 7 ( Fig. 2 and Supplemental Fig. 1 ). Pharmacological identification uses two separate processes to identify receptors. First, endogenous agonist binding is used to identify the receptor, which in the case of native OKP cells femtomolar levels of ANG II bind to the cells (Fig. 6A) . Second, specific inhibitors are used to further classify the receptor and denote receptor subtype, which in the case of native OKP cells fails to identify the AT 1 R because of a lack of interaction with ARBs (Figs. 6C and 7) . Because of the following data, we conclude that native OKP cells express functional AT 1 Rs that do not bind ARBs: 1) the genetic identification of an AT 1 R in native OKP cells; 2) the binding of ANG II to native OKP cells, and failure for PD-123319 to compete for binding; and 3) ANG II-mediated phosphorylation of Jak2 in native OKP cells, which is known to occur through a conserved YIPP motif (18) on the AT 1 R and not the AT 2 R.
Previous studies have identified multiple residues on the AT 1 R that interact with ARBs (18, 21, 24, 26, 38) (Figs. 1 and  3 ). Systematic mutagenesis of these sites individually or in combination led to decreased binding affinity of ARBs. Furthermore, reversal of some of these mutations led to a return to normal binding characteristics of the AT 1 R (17). However, because these are mutagenesis studies, some of the sites may not be directly involved in binding the ARB yet may alter the structure of the receptor or its binding pocket. Specifically, L300 and F301 are probably not directly involved in ARB binding, since they are at the cytosolic surface of the receptor; thus, we shade them yellow in Fig. 1 and exclude them from Fig. 3 to indicate their questionable significance (18) . Similarly, H256 (6.51) appears to be partially involved in ARB binding, but only when substituted with Arg, not Gln, Ala, and Glu (26) . Both Arg and His are positively charged, and removing or altering the charge has no effect on binding. However, Arg is larger than His, and with H256 (6.51) being near the pocket the alteration in binding is because of an altered shape of the pocket rather than direct interference with ARB binding. The amino acid variation from the normal mammalian sequence at position 108 seen in the opossum AT 1 R (Ile compared with the predominant Val) is identical to the experimentally established mutagenesis studies in rat AT 1A R (V108I) that leads to an approximate 40-fold decrease in ARB-binding affinity (24) . These observations suggest that ARB binding to position 108 is dependent on the size of the R group: Ile (larger than Val) and Ala (smaller than Val), and, while both substitutions disrupt binding, they do so to different extents. Therefore, there is likely a hydrophobic interaction between the ARB and AT 1 R that is specifically supported by V108. Moreover, replacement of I108 of Xenopus AT 1 R with Val and other minor alterations restores ARB binding to the receptor (18) . Because this difference in sequence exists in two of the examined mammalian species [opossum and gerbil (Supple- Table 1 )], this single amino acid is likely a key factor in the loss of ARB binding and may be a single polymorphism that can confer ARB resistance in humans.
A second prominent OKP variation is at position 163, which in the human AT 1 R is normally an Ala but in the opossum is a Val. In the rat AT 1A R, mutation of A163 to Thr leads to a 12-fold decrease in losartan inhibition of ANG II binding (17) . Interestingly, this is also the site where an amino acid change of a verified human agtr1 polymorphism results in a sevenfold decreased binding of losartan (1) . Similarly, T163 is the endogenous residue in bovine AT 1 R, and, although bovine AT 1 Rs are inhibited by ARBs, losartan (Dup 753) is 10-fold less potent at the bovine AT 1 R compared with the rat AT 1 R (2). These data strongly indicate that position 163 is important to ARB binding; however, it remains to be determined what magnitude change in ARB binding would occur in an A163V mutant.
In addition to positions 108 and 163, the opossum differs from the human AT 1 R at positions 107, 192, and 198. S107 (3.25) in the rat AT 1A R, which is identical to the human, has been shown to contribute weakly to ARB binding (17) . In the opossum AT 1 R, position 107 is a Gly and thus may contribute to the lack of ARB binding. Positions 192 and 198 were previously mutated to Met and Ala, respectively, in the rat AT 1A R, and each alteration resulted in approximately twofold reduction in ARB affinity for the receptor when singly mutated (17) . The human AT 1 R contains P192 and T198, whereas the opossum contains L192 and S198. Substituting a Leu for Pro is not as dramatic as Met, but the loss of a Pro most likely changes the shape of the binding pocket. Substituting a Ser for a Thr likely has little effect on ARB binding. Thus, in the opossum, the presence of L192 likely contributes to the effects of I108 and V163 on ARB affinity, whereas G107 and S198 are unlikely to greatly alter ARB binding.
Many investigators have modeled the AT 1 R based on mutagenesis studies and/or the crystal structure of rhodopsin. We propose an alternative model that is largely based on the recent ␤ 2 -AR crystal structure (32) . Although two-dimensional modeling of the ␣-helixes fails to demonstrate the greater tertiary structure, it does provide structural insight into the general shape of the receptor. Four points are unique in this model: the broken TMI ␣-helix, the small ␣-helix in intracellular loop 2 (ICL2), the incomplete ␣-helix found in TMIII and TMVII, as well as the ␣-helix in ECL2. Because this model was prepared with a view toward the ␤ 2 -AR crystal structure, this approach has identified some of the structures that have been lost in standard models. Importantly, it is known that TMVII is adjacent to TMII, as is denoted by the disulfide bond, and this change in orientation also moves cysteines that form the second disulfide bond between the ␣-helix of TMIII and ECL2 into closer proximity. However, for this last disulfide bond to form, the ECL2 ␣-helix will have to lay across the receptor like a lid, as seen in the ␤ 2 -AR. Last, TMV will likely traverse the membrane at an angle.
Collectively, the current and prior studies bring to light the importance of AT 1 R polymorphisms in the human population that are not responsive to the therapeutic effects of ARBs. Most studies focus on unraveling a link between AT 1 R polymorphisms and high blood pressure and other cardiovascular diseases, whereas there has been very little exploration for polymorphisms conferring resistance to ARBs. In this context, our finding that ARB resistance can be traced to natural variations from the canonical mammalian sequence within the ARBbinding pocket is particularly relevant. Hence, it is tempting to speculate that humans that are resistant to ARBs may harbor these or other variations in their AT 1 R gene that may predispose ARB resistance (10, 37) . A systematic analysis of the agtr1 gene should be conducted to determine: if there are polymorphisms that confer ARB resistance and are clinically relevant, which amino acids are altered in the AT 1 R, and what percentages of the population carry these polymorphisms (Supplemental Table 2 ).
ARBs have become the mainstay in treatment of high blood pressure, more so in the context of reduction in cardiovascular risk and slowing progression of chronic kidney disease. Importantly, the National Kidney Foundation and the American Heart Association have issued Grade A recommendation for the use of ARBs for reduction in proteinuria in type 2 diabetes, hypertension, and cardiovascular disease (19a) . It has been well known over the past several years that ARBs are not equipotent in all patients; yet, ARBs have proven superior to other BP-lowering medications when it comes to cardiovascular risk reduction in the aforementioned patients. It follows then that ARB resistance can be a major problem in the effective therapeutic management of this group of patients.
